A neurosurgeon in the UK has lost his 2013 paper on spinal surgery in the British Journal of Neurosurgery for doing what appears to have been an end-run around the folks that did the work.
The article, “The management of spinal dural fistulas: a 13-year retrospective analysis,” was written by Denosshan Sri, of Addenbrooke’s Hospital, in Cambridge.
Here’s the abstract:
Introduction. Spinal Dural Fistulas (SDAVF) are the most common Spinal Vascular Malformation. The management of SDAVFs has revolved around embolization or surgical interruption. The management strategy employed at this centre is to attempt embolization as first line therapy and to opt for surgery in the event of failure. Method. This retrospective study looks at the management of 38 patients treated for SDAVFs at a tertiary centre over a 13-year period (1997–2010). Patient demographics, procedure and follow-up over a 6–12 month period (mean of approximately 10 months) were analyzed and qualitative assessment of patient outcome was assessed. Results. Patient ages ranged from 20 to 86 (mean 63.5), with 27 male and 11 female patients. Patients managed since 1995 with a combination of embolization and surgery report either improved symptoms or a return to normal were 73.7%. Micturition and bowel symptoms indicated more severe disability and were more likely to contribute to no improvement in overall outcome. Conclusions. This centre has in place a management strategy for SDAVF that contributes to both radiologically and symptomatically successful treatment.
Trouble is, it seems the center didn’t know about the article. According to the retraction notice:
The retraction has been requested on the grounds that the study leaders had not participated in or agreed to the submitted article. The retraction is not made on the basis of any concerns with the data or findings of the study.
D. Sri sincerely apologises for the inconvenience caused.
The paper has yet to be cited, according to Thomson Scientific’s Web of Knowledge.
Like Retraction Watch? Consider supporting our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, and sign up on our homepage for an email every time there’s a new post.